dc.description.abstract | Renal dysfunction is common in clinical settings in which cardiac function is compromised such as heart failure, cardiac surgery or sepsis, and is associated with high morbidity and mortality. Levosimendan is a calcium sensitizer and potassium channel opener used in the treatment of acute heart failure. This review describes the effects of the inodilator levosimendan on renal function. A panel of 25 scientists and clinicians from 15 European countries (Austria, Finland, France, Hungary, Germany, Greece, Italy, Portugal, the Netherlands, Slovenia, Spain, Sweden, Turkey, the United Kingdom, and Ukraine) convened and reached a consensus on the current interpretation of the renal effects of levosimendan described both in non-clinical research and in clinical study reports. Most reports on the effect of levosimendan indicate an improvement of renal function in heart failure, sepsis and cardiac surgery settings. However, caution should be applied as study designs differed from randomized, controlled studies to uncontrolled ones. Importantly, in the largest HF study (REVIVE I and II) no significant changes in the renal function were detected. As it regards the mechanism of action, the opening of mitochondrial K-ATP channels by levosimendan is involved through a preconditioning effect. There is a strong rationale for randomized controlled trials seeking beneficial renal effects of levosimendan. As an example, a study is shortly to commence to assess the role of levosimendan for the prevention of acute organ dysfunction in sepsis (LeoPARDS). | en_US |
dc.contributor.department | [Yilmaz, Mehmet B.] Cumhuriyet Univ, Sch Med, Dept Cardiol, Sivas, Turkey -- [Grossini, Elena] Univ Piemonte Orientale, Lab Fisiol, Dipartimento Med Traslaz, Piemonte, Italy -- [Silva Cardoso, Jose C.] Univ Porto, Fac Med, P-4100 Oporto, Portugal -- [Edes, Istvan] Univ Debrecen, Inst Cardiol, Med & Hlth Sci Ctr, H-4012 Debrecen, Hungary -- [Fedele, Francesco -- Morelli, Andrea] Univ Roma La Sapienza, Dept Cardiovasc Resp Nephrol & Geriatr Sci, I-00185 Rome, Italy -- [Pollesello, Piero -- Kivikko, Matti] Orion Pharma, Cardiol & Crit Care, Espoo, Finland -- [Harjola, Veli-Pekka] Helsinki Univ Hosp, Dept Cardiol, Helsinki, Finland -- [Hasslacher, Julia] Univ Klin Innere Med, Innsbruck, Austria -- [Mebazaa, Alexandre] Univ Paris, Dept Anaesthesia & Intens Care, INSERM UMR 942, Lariboisiere Hosp, F-75252 Paris, France -- [le Noble, Jos] VieCuri Med Ctr, Dept Intens Care, Venlo, Netherlands -- [Oldner, Anders] Karolinska Inst, Dept Physiol & Pharmacol, Sect Anaesthesiol & Intens CareMed, Stockholm, Sweden -- [Oulego Erroz, Ignacio -- Rodriguez Fernandez, Luis M.] Complejo Asistencial Univ Leon, Dept Pediat, Leon, Spain -- [Parissis, John T.] Attikon Univ Hosp, Heart Failure Unit, Athens, Greece -- [Parkhomenko, Alexander] Natl Sci Ctr, Strazhesko Inst Cardiol, Kiev, Ukraine -- [Poelzl, Gerhard] Med Univ Innsbruck, Dept Cardiol, A-6020 Innsbruck, Austria -- [Rehberg, Sebastian] Univ Munster, Dept Anesthesiol Intens Care & Pain Med, D-48149 Munster, Germany -- [Ricksten, Sven-Erik] Sahlgrens Univ Hosp, Dept Cardiothorac Anesthesia & Intens Care, Gothenburg, Sweden -- [Salmenpera, Markku] Helsinki Univ Hosp, Dept Anesthesiol & Intens Care Med, Helsinki, Finland -- [Singer, Mervyn] UCL, London, England -- [Treskatsch, Sascha] Charite, Dept Anesthesiol & Intens Care Med, Campus Charite Mitte, D-13353 Berlin, Germany -- [Treskatsch, Sascha] Campus Virchow Klinikum, Berlin, Germany -- [Vrtovec, Bojan] Univ Ljubljana, Med Ctr, Adv Heart Failure & Transplantat Ctr, Dept Cardiol, Ljubljana 61000, Slovenia -- [Wikstrom, Gerhard] Uppsala Univ, Akad Sjukhuset, Kardiologkliniken, Uppsala, Sweden | en_US |